A5041180818- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Cancer Research and Treatments
- Intraperitoneal and Appendiceal Malignancies
- Renal cell carcinoma treatment
- Hepatitis C virus research
- Economic and Technological Systems Analysis
- Stock Market Forecasting Methods
- Metastasis and carcinoma case studies
- Cancer, Hypoxia, and Metabolism
- Fibroblast Growth Factor Research
- Management of metastatic bone disease
- Complex Systems and Time Series Analysis
- Liver physiology and pathology
- Cancer Immunotherapy and Biomarkers
Moscow Institute of Physics and Technology
2021
Regional Public Health Care Institution "City Hospital No. 5, Barnaul"
2020
Russian Cancer Research Center NN Blokhin
2012-2017
Russian Academy of Sciences
2014
Cancer Research Center
2014
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study plus pembrolizumab (an anti–PD-1 antibody) unresectable HCC (uHCC). PATIENTS AND METHODS In this open-label multicenter study, patients uHCC received (bodyweight ≥ 60 kg, 12 mg; < 8 mg) orally daily and...
4519 Background: LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT, approved for first line (1L) treatment uHCC. PEMBRO, an anti-PD-1 monoclonal antibody, was granted accelerated approval the patients (pts) with HCC after sorafenib therapy. We assessed safety efficacy + PEMBRO in Methods: In this phase 1b trial (NCT03006926), pts received 12 mg/day (bodyweight [BW] ≥60 kg) or 8 (BW <60 orally 200 mg IV on Day 1 21-day cycle. Primary endpoints were tolerability...
Objective: to study influence of preoperative chemotherapy on postoperative complications rate. Material and methods: an analysis 455 cases extensive liver resection. 229 (56%) patients didn’t receive neoadjuvant chemotherapy, 176 (44%) - received chemotherapy. 216 (53%) had bilobar lesions, 156 (39%) multiple metastases, 168 (42%) synchronous 237 (58%) metachronous metastases. 60 (15%) in addition been resected for extrahepatic Results: bevacizumab inckusion regional did not lead increase...
Aim of the study. To estimate an influence Cavitron ultrasonic surgical aspirator (CUSA) on intraoperative blood loss. Material and methods. An analysis 185 cases extensive liver resections in patients for colorectal metastases has been performed. All were assigned to CUSA group (n = 56) or clamp crashing 129). Patients from first received regional FOLFOX6 + bevacizumab chemotherapy. Preoperative chemotherapy did not performed second patients. Results. Liver transection with lead decline...
This paper describes the results of using ADAM (Adaptive Deep Autonomous Machine) architecture in task predicting movements financial markets. In addition, data transform algorithm has been developed that converts their distribution over each coordinates similar to a uniform one.
Colorectal cancer (CRC) is one of the most common malignancies, occupying third place in world among malignant tumors morbidity rate and 4th on causes death. Every year there are diagnosed more than 1.3 millions new cases disease. The mortality continues to be structure incidence. In Russia, each 60 thousands colorectal cancer. For last time incidence increased by 11%, out them 17 patients show newly distant metastases. absolute majority metastases liver firstly detected 2-3 years. Liver...
Objective: to study influence of regional chemo- and biotherapy on intraoperative blood loss. Materials methods: An analysis 122 cases extensive liver resection accompanied with chemotherapy in colorectal metastases patients has been performed. 69 (57%) them had bilobar lesions, 58 (48%) - multiple metastases, 27 (22%) resected for extrahepatic metastases. Results: bevacizumab inclusion preoperative did not lead increase Conclusion: Median loss was 1200 ml both groups. Up 6 courses antitumor...